Cookson Peirce & Co. Inc. Takes $2.67 Million Position in Lantheus Holdings, Inc. $LNTH

Cookson Peirce & Co. Inc. acquired a new position in Lantheus Holdings, Inc. (NASDAQ:LNTH) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 24,060 shares of the medical equipment provider’s stock, valued at approximately $2,669,000.

A number of other hedge funds also recently bought and sold shares of the stock. Jupiter Topco LLC purchased a new stake in Lantheus during the second quarter valued at approximately $575,628,000. Farallon Capital Management LLC increased its position in shares of Lantheus by 56.1% during the fourth quarter. Farallon Capital Management LLC now owns 5,427,479 shares of the medical equipment provider’s stock worth $361,199,000 after purchasing an additional 1,950,252 shares in the last quarter. Norges Bank acquired a new position in shares of Lantheus during the fourth quarter worth $76,197,000. Freestone Grove Partners LP lifted its holdings in shares of Lantheus by 4,114.8% during the 4th quarter. Freestone Grove Partners LP now owns 608,526 shares of the medical equipment provider’s stock valued at $40,497,000 after purchasing an additional 594,088 shares during the last quarter. Finally, Assenagon Asset Management S.A. boosted its position in shares of Lantheus by 440.3% in the 2nd quarter. Assenagon Asset Management S.A. now owns 714,980 shares of the medical equipment provider’s stock worth $79,320,000 after purchasing an additional 582,661 shares in the last quarter. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently issued reports on the company. B. Riley Financial lowered Lantheus from a “buy” rating to a “hold” rating in a research report on Monday, August 17th. Wall Street Zen downgraded Lantheus from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th. William Blair set a $102.50 price target on Lantheus in a research note on Monday, August 3rd. TD Cowen downgraded shares of Lantheus from a “buy” rating to a “hold” rating and cut their price objective for the company from $110.00 to $102.50 in a report on Monday, August 3rd. Finally, Leerink Partners set a $102.50 price objective on shares of Lantheus in a research report on Monday, August 3rd. Four analysts have rated the stock with a Buy rating and ten have given a Hold rating to the stock. Based on data from MarketBeat, Lantheus presently has an average rating of “Hold” and an average target price of $108.11.

Lantheus Price Performance

Shares of Lantheus stock opened at $100.77 on Friday. The company has a quick ratio of 2.89, a current ratio of 3.06 and a debt-to-equity ratio of 0.43. Lantheus Holdings, Inc. has a twelve month low of $49.67 and a twelve month high of $111.86. The business has a 50-day moving average price of $103.74 and a 200 day moving average price of $91.58. The firm has a market cap of $6.58 billion, a PE ratio of 24.34 and a beta of -0.03.

Lantheus (NASDAQ:LNTH) last released its earnings results on Thursday, August 6th. The medical equipment provider reported $1.55 earnings per share for the quarter, beating the consensus estimate of $1.30 by $0.25. Lantheus had a return on equity of 28.10% and a net margin of 17.69%.The business had revenue of $388.18 million for the quarter, compared to the consensus estimate of $363.23 million. During the same quarter last year, the business posted $1.57 earnings per share. The business’s quarterly revenue was up 2.7% compared to the same quarter last year. Sell-side analysts predict that Lantheus Holdings, Inc. will post 4.48 earnings per share for the current fiscal year.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.